Scarica l'app Stockscreener
0.639
2.16%
0.0135
Pre-mercato:
.64
0.001
+0.16%
Precedente Chiudi:
$0.6255
Aprire:
$0.65
Volume 24 ore:
89,409
Relative Volume:
0.14
Capitalizzazione di mercato:
$20.71M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-7.2449
EPS:
-0.0882
Flusso di cassa netto:
-
1 W Prestazione:
-14.69%
1M Prestazione:
-1.84%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.5998
$0.65
Intervallo di 1 settimana:
$0.55
$0.745
Portata 52W:
$0.55
$19.51
Jupiter Neurosciences Inc Stock (JUNS) Company Profile
Nome
Jupiter Neurosciences Inc
Settore
Industria
Telefono
(561) 406-6154
Indirizzo
1001 NORTH US HWY 1, JUPITER
Confronta JUNS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JUNS
Jupiter Neurosciences Inc
|
0.639 | 20.71M | 0 | 0 | 0 | -0.0882 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Jupiter Neurosciences Inc Borsa (JUNS) Ultime notizie
Jupiter Neurosciences Inc. (JUNS) reports earnings - Quartz
Jupiter Neurosciences faces NASDAQ delisting over share price By Investing.com - Investing.com South Africa
Jupiter Neurosciences faces NASDAQ delisting over share price - Investing.com
Jupiter Neurosciences, Catalent Partner to Produce JOTROL Softgels for Upcoming Trial - Contract Pharma
Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Bluefield Daily Telegraph
Jupiter Neurosciences and Aquanova AG Announce Strategic - GlobeNewswire
Jupiter Neurosciences, Aquanova announce strategic collaboration - TipRanks
Jupiter Neurosciences partners with Aquanova on health products By Investing.com - Investing.com South Africa
Jupiter Neurosciences And Aquanova AG Announce Strategic Collaboration To Develop Longevity And Healthspan Products - Marketscreener.com
Jupiter Neurosciences partners with Aquanova on health products - Investing.com
Can Jupiter Neurosciences Capture The $44B Longevity Market With Its New Aquanova Partnership? - StockTitan
Jupiter Neurosciences Inc (JUNS) Shares Decline Despite Market Challenges - The News Heater
Jupiter Neurosciences partners with Catalent for Parkinson’s trial By Investing.com - Investing.com Nigeria
Three technology stocks with differentiated value propositions | 2025-02-07 | Investing News - Stockhouse Publishing
Jupiter Neurosciences partners with Catalent for Parkinson's trial - MSN
Jupiter Neurosciences Addresses Market Volatility as it - GlobeNewswire
Jupiter Neurosciences says volatility ‘appears to be driven by misconceptions’ - TipRanks
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - TradingView
Inside Jupiter's $50B Market Strategy: NIH Funding Secured, Phase 2 Trials Set for Revolutionary CNS Treatment - Stock Titan
Jupiter Neurosciences Partners With Catalent For Parkinson's JOTROL Trial Production - Nasdaq
Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules - Marketscreener.com
Jupiter Neurosciences Partners with Catalent to Produce JOTROL Softgels for Upcoming Clinical Trial - Contract Pharma
Jupiter Neurosciences partners with Catalent for Parkinson's trial By Investing.com - Investing.com South Africa
Clinical Trials News Live Feed - StockTitan
Jupiter Neurosciences Announces JOTROL Manufacturing - GlobeNewswire
Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial - The Manila Times
Major Breakthrough: New Parkinson's Drug Manufacturing Deal Could Fast-Track Treatment for 10M Patients - StockTitan
Phase 2a trial of Jotrol as treatment for Parkinson’s planned - Parkinson's News Today
Jupiter Neurosciences partners with Zina for Parkinson's trial - Investing.com India
Jupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study - Marketscreener.com
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial - GlobeNewswire
Jupiter Neurosciences partners with Zina for Parkinson's trial By Investing.com - Investing.com South Africa
Jupiter Neurosciences Partners With Zina Biopharmaceuticals To Launch Phase 2a Parkinson's Trial - Nasdaq
Wall Street Set to Open Slightly Lower Friday as Investors Await PMI, Housing Figures - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
United States shares higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com UK
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Stock market news: Chanson International Holdings declined by 83.97% while Dogwood Therapeutics surged by 387.32% during mid day trading - Business Upturn
Stock market today: Icon Energy surged by 222.66% while Jupiter Neurosciences gained over 208.62% in early trading - Business Upturn
US Stocks Mixed; GE Aerospace Posts Upbeat Earnings - Benzinga
Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024 - News & Insights
Stock market news: Star Fashion Culture Holdings -78.42%, Lisata Therapeutics -33.08% among biggest losers in early trading - Business Upturn
Stock market today: Star Fashion Culture Holdings -79.05%, Lisata Therapeutics -23.34% among biggest losers in early trading - Business Upturn
Twin Vee PowerCats Co. New 5-Axis CNC Router to Harness Advanced Robotics in Production Process - The Globe and Mail
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online
Jupiter Neurosciences refocuses on NLRP3 inflammasome By Investing.com - Investing.com South Africa
Jupiter Neurosciences refocuses on NLRP3 inflammasome - Investing.com India
Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials - GlobeNewswire
Jupiter Neurosciences announces focus on NLRP3 pathway in JOTROL trials - TipRanks
Jupiter Neurosciences Inc Azioni (JUNS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):